Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286

Endothelial cell infection and endotheliitis in COVID-19

Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30937-5 · Cited by 6,358

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 5,036

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury

Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445

A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9

Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

MAGRO, C. M. J., Mulvey, J. J., Berlin, D., Nuovo, G. J., Salvatore, S., Harp, J., Baxter-Stoltzfus, A., & Laurence, J. C. (2020) · Translational research · doi:10.1016/j.trsl.2020.04.007 · Cited by 2,224

International Union of Pharmacology. XXIII. The Angiotensin II Receptors

Marc De Gasparo, B., Catt, K. J., Inagami, T., Wright, J. W., & Unger, T. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01458-3 · Cited by 2,131

Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19

Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Liu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., Wang, Z., Li, J., Li, J., Feng, C., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1643-8 · Cited by 2,056

Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor

Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005) · Science · doi:10.1126/science.1116480 · Cited by 2,035

Pharmacology of bradykinin and related kinins.

Regoli, D. C., & Barabé, J. (1980) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06836-x · Cited by 1,900

Bioregulation of kinins: kallikreins, kininogens, and kininases.

Bhoola, K. D., Figueroa, C. D., & Worthy, K. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00058-4 · Cited by 1,744

Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Quan, S., Zhang, F., Sun, R., Qian, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.032 · Cited by 1,514

Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase

Vickers, C., Hales, P., Kaushik, V. K., Dick, L. R., Gavin, J. M., Tang, J., Godbout, K., Parsons, T. F., Baronas, E., Hsieh, F., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200581200 · Cited by 1,406

The ACE2/angiotensin-(1-7)/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1-7)

Santos, R. A. S., Sampaio, W. O., Alzamora, A. C., Motta-Santos, D., Alenina, N., Bader, M., & Campagnole-Santos, M. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2016 · Cited by 1,144

Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology

Forrester, S. J., Booz, G. W., Sigmund, C. D., Coffman, T. M., Kawai, T., Rizzo, V., Scalia, R. G., & Eguchi, S. (2018) · Physiological Reviews · doi:10.1152/physrev.00038.2017 · Cited by 1,135

Generation of C5a in the absence of C3: a new complement activation pathway

Huber-Lang, M. S., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., Lambris, J. D., Warner, R. L., Flierl, M. A., Hoesel, L. M., et al. (2006) · Nature Medicine · doi:10.1038/nm1419 · Cited by 976

International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences

Leeb-Lundberg, L. M. F., Marceau, F., Müller‐Esterl, W., Pettibone, D. J., & Zuraw, B. L. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.2 · Cited by 956

Overview of complement activation and regulation

Noris, M., & Remuzzi, G. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.001 · Cited by 864

Platelet Polyphosphates Are Proinflammatory and Procoagulant Mediators In Vivo

Müller, F., Mutch, N. J., Schenk, W. A., Smith, S. A., Esterl, L., Spronk, H. M. H., Schmidbauer, S., Gahl, W. A., Morrissey, J. H., & Renné, T. (2009) · Cell · doi:10.1016/j.cell.2009.11.001 · Cited by 848

Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure

Patel, V. B., Zhong, J.-C., Grant, M. B., & Oudit, G. Y. (2016) · Circulation Research · doi:10.1161/circresaha.116.307708 · Cited by 833

Angiotensin II revisited: new roles in inflammation, immunology and aging

Benigni, A., Cassis, P., & Remuzzi, G. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000080 · Cited by 757

The role of the anaphylatoxins in health and disease

Klos, A., Tenner, A. J., Johswich, K.-O., Ager, R. R., Reis, E. S., & Köhl, J. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.027 · Cited by 730

Molecular Intercommunication between the Complement and Coagulation Systems

Amara, U., Flierl, M. A., Rittirsch, D., Klos, A., Chen, H., Acker, B., Brückner, U. B., Nilsson, B., Gebhard, F. T., Lambris, J. D., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903678 · Cited by 719

Plasma bradykinin in angio-oedema

Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., & Agostoni, A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09137-x · Cited by 706

Bradykinin and inflammatory pain

Dray, A., & Perkins, M. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90133-7 · Cited by 653

Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism

Rice, G., Thomas, D. A., Grant, P. J., Turner, A. J., & Hooper, N. M. (2004) · Biochemical Journal · doi:10.1042/bj20040634 · Cited by 619

The B1 Receptors for Kinins

Marceau, F., Hess, J. F., & Bachvarov, D. R. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01371-1 · Cited by 604

Contact System: A Vascular Biology Modulator With Anticoagulant, Profibrinolytic, Antiadhesive, and Proinflammatory Attributes

Colman, R. W., & Schmaier, A. H. (1997) · Blood · doi:10.1182/blood.v90.10.3819 · Cited by 582

Counter-regulatory renin–angiotensin system in cardiovascular disease

Paz Ocaranza, M., Riquelme, J. A., García, L., Jalil, J. E., Chiong, M., Santos, R. A. S., & Lavandero, S. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0244-8 · Cited by 561

Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation

Tsutsumi, Y., Matsubara, H., Masaki, H., Kurihara, H., Murasawa, S., Takai, S., Miyazaki, M., Nozawa, Y., Ozono, R., Nakagawa, K., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7886 · Cited by 560

Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase

Bokisch, V. A., & Müller‐Eberhard, H. J. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106462 · Cited by 517

Neutrophil Extracellular Traps Promote Thrombin Generation Through Platelet-Dependent and Platelet-Independent Mechanisms

Gould, T. J., Vu, T. T., Swystun, L. L., Dwivedi, D. J., Safiah, H. C., Weitz, J. I., & Liaw, P. C. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304114 · Cited by 514

The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease

Remuzzi, G., Perico, N., Macia, M. L., & Ruggenenti, P. L. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09911.x · Cited by 513

T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 + T cells

Arbore, G., West, E. E., Spolski, R. J., Robertson, A. A. B., Klos, A., Rheinheimer, C., Dutow, P., Woodruff, T. M., Yu, Z., O'Neill, L. A. J., et al. (2016) · Science · doi:10.1126/science.aad1210 · Cited by 513

AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration

AbdAlla, S., Lother, H., & Quitterer, U. (2000) · Nature · doi:10.1038/35024095 · Cited by 503

The Angiotensin II AT2 Receptor Is an AT1Receptor Antagonist

AbdAlla, S., Lother, H., Abdel-Tawab, A. M., & Quitterer, U. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105253200 · Cited by 462

Expression cloning of a human B1 bradykinin receptor.

Menke, J. G., Borkowski, J. A., Bierilo, K. K., MacNeil, T., Derrick, A., Schneck, K., Ransom, R. W., Strader, C. D., Linemeyer, D. L., & Hess, J. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31844-6 · Cited by 459

Complement Proteins C5b-9 Induce Secretion of High Molecular Weight Multimers of Endothelial von Willebrand Factor and Translocation of Granule Membrane Protein GMP-140 to the Cell Surface

Hattori, R., Hamilton, K. K., McEver, R. P., et al. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)81901-9 · Cited by 442

Discovery and Characterization of Alamandine

Lautner, R. Q., Villela, D. C., Fraga-Silva, R. A., Silva, N., Verano‐Braga, T., Costa-Fraga, F. P., Jankowski, J., Jankowski, V., Sousa, F. B. D., Alzamora, A. C., et al. (2013) · Circulation Research · doi:10.1161/circresaha.113.301077 · Cited by 440

Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation

Gao, T., Hu, M., Zhang, X., Li, H., Zhu, L., Liu, H., Dong, Q., Zhang, Z., Wang, Z., Hu, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1101/2020.03.29.20041962 · Cited by 435

The dark side of C5a in sepsis

Ward, P. A. (2004) · Nature reviews. Immunology · doi:10.1038/nri1269 · Cited by 420

C3 glomerulopathy — understanding a rare complement-driven renal disease

Smith, R. J., Appel, G. B., Blom, A. M., Cook, H. T., D’Agati, V. D., Fakhouri, F., Frémeaux‐Bacchi, V., Józsi, M., Kavanagh, D., Lambris, J. D., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0107-2 · Cited by 413

Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients

Holter, J. C., Pischke, S. E., de Boer, E., Lind, A., Jenum, S., Holten, A. R., Tonby, K., Barratt‐Due, A., Sokolova, M., Schjalm, C., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2010540117 · Cited by 405

Human recombinant soluble ACE2 in severe COVID-19

Zoufaly, A., Poglitsch, M., Aberle, J. H., Hoepler, W., Seitz, T., Traugott, M. T., Grieb, A., Pawelka, E., Laferl, H., Wenisch, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30418-5 · Cited by 401

A journey through the lectin pathway of complement— MBL and beyond

Garred, P., Genster, N., Pilely, K., Bayarri‐Olmos, R., Rosbjerg, A., Ma, Y. J., & Skjoedt, M. (2016) · Immunological Reviews · doi:10.1111/imr.12468 · Cited by 399

Platelet activation leads to activation and propagation of the complement system

Conde, I. D., Crúz, M. A., Zhang, H., López, J. A., & Afshar‐Kharghan, V. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041497 · Cited by 397

Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition

Yu, J. M., Yuan, X., Chen, H., Chaturvedi, S., Braunstein, E. M., & Brodsky, R. A. (2020) · Blood · doi:10.1182/blood.2020008248 · Cited by 388

Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis

Henry, B. M., Vikse, J., Benoit, S. W., Favaloro, E. J., & Lippi, G. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.04.027 · Cited by 381

A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm

Garvin, M. R., Alvarez, C., Miller, J. I., Prates, E. T., Walker, A. M., Amos, B. K., Mast, A. E., Justice, A. C., Aronow, B. J., & Jacobson, D. (2020) · eLife · doi:10.7554/elife.59177 · Cited by 372

Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects

Haschke, M., Schuster, M., Poglitsch, M., Loibner, H., Salzberg, M. O., Bruggisser, M., Penninger, J. M., & Krähenbühl, S. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0072-7 · Cited by 362

Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome

Manuelian, T., Hellwage, J., Meri, S., Caprioli, J., Noris, M., Heinen, S., Józsi, M., Neumann, H. P. H., Remuzzi, G., & Zipfel, P. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16651 · Cited by 350

Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex.

Hamilton, K. K., Hattori, R., Esmon, C. T., & Sims, P. J. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39666-8 · Cited by 349

Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q.

Ghebrehiwet, B., Lim, B. L., Peerschke, E. I. B., Willis, A. C., & Reid, K. B. M. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.6.1809 · Cited by 347

The renin-angiotensin system: going beyond the classical paradigms

Santos, R. A. S., Oudit, G. Y., Verano‐Braga, T., Canta, G., Steckelings, U. M., & Bäder, M. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00723.2018 · Cited by 347

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure

Coulson, L. B., Danser, A. H. J., Poglitsch, M., Touyz, R. M., Burnett, J. C. J., Llorens‐Cortés, C., Ehlers, M. R., & Sturrock, E. D. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017129 · Cited by 346

A Factor XIIa Inhibitory Antibody Provides Thromboprotection in Extracorporeal Circulation Without Increasing Bleeding Risk

Larsson, M., Rayzman, V., Nolte, M. W., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3006804 · Cited by 340

The case of complement activation in COVID-19 multiorgan impact

Noris, M., Benigni, A., & Remuzzi, G. (2020) · Kidney International · doi:10.1016/j.kint.2020.05.013 · Cited by 337

THE INHIBITION OF PLASMIN, PLASMA KALLIKREIN, PLASMA PERMEABILITY FACTOR, AND THE C'1r SUBCOMPONENT OF THE FIRST COMPONENT OF COMPLEMENT BY SERUM C'1 ESTERASE INHIBITOR

Ratnoff, O. D., Pensky, J., Ogston, D., & Naff, G. B. (1969) · The Journal of Experimental Medicine · doi:10.1084/jem.129.2.315 · Cited by 334

Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration

Sodhi, C. P., Wohlford-Lenane, C., Yamaguchi, Y., Prindle, T., Fulton, W. B., Wang, S., McCray, P. B., Chappell, M. C., Hackam, D. J., & Jia, H. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00498.2016 · Cited by 332

Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.

Diurno, F., Numis, F. G., Porta, G., et al. (2020) · PubMed · doi:10.26355/eurrev_202004_20875 · Cited by 327

Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS

Patel, V. B., Clarke, N. E., Wang, Z., Dong, F., Parajuli, N., Basu, R., Putko, B. N., Kassiri, Z., Turner, A. J., & Oudit, G. Y. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.11.017 · Cited by 321

Angiotensin II Increases Vascular Permeability Factor Gene Expression by Human Vascular Smooth Muscle Cells

Williams, B., Baker, A. Q., Gallacher, B., & Lodwick, D. (1995) · Hypertension · doi:10.1161/01.hyp.25.5.913 · Cited by 301

Complement-mediated regulation of tissue factor activity in endothelium.

Saadi, S., Holzknecht, R. A., Patte, C. P., et al. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.6.1807 · Cited by 295

Structures of C3b in Complex with Factors B and D Give Insight into Complement Convertase Formation

Forneris, F., Ricklin, D., Wu, J., Τζέκου, Α., Wallace, R. S., Lambris, J. D., & Gros, P. (2010) · Science · doi:10.1126/science.1195821 · Cited by 289

Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome

van de Veerdonk, F. L., Netea, M. G., van Deuren, M., van der Meer, J. W. M., de Mast, Q., Brüggemann, R. J. M., & van der Hoeven, H. (2020) · eLife · doi:10.7554/elife.57555 · Cited by 286

Immunosuppressive Treatment Protects Against Angiotensin II-Induced Renal Damage

Müller, D. N., Shagdarsuren, E., Park, J.-K., Dechend, R., Mervaala, E. M. A., Hampich, F., Fiebeler, A., Ju, X., Finckenberg, P., Theuer, J., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64445-8 · Cited by 281

Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system

Yeung, M. L., Teng, J. L. L., Jia, L., Zhang, C., Huang, C., Cai, J., Zhou, R., Chan, K., Zhao, H., Zhu, L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.053 · Cited by 276

Simultaneous Activation of Complement and Coagulation by MBL-Associated Serine Protease 2

Krarup, A., Wallis, R., Presanis, J. S., Gál, P., & Sim, R. B. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000623 · Cited by 263

Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging

Propson, N. E., Roy, E. R., Litvinchuk, A., Köhl, J., & Zheng, H. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140966 · Cited by 258

Coagulation factor XII in thrombosis and inflammation

Maas, C., & Renné, T. (2018) · Blood · doi:10.1182/blood-2017-04-569111 · Cited by 257

Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy

Mastellos, D. C., Pires da Silva, B. G. P., Fonseca, B. A. L., Fonseca, N. P., Auxiliadora-Martins, M., Mastaglio, S., Ruggeri, A., Sironi, M., Radermacher, P., Chrysanthopoulou, A., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108598 · Cited by 255

Identification and Characterization of Prolylcarboxypeptidase as an Endothelial Cell Prekallikrein Activator

Shariat‐Madar, Z., Mahdi, F., & Schmaier, A. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106101200 · Cited by 253

Complement activation on platelets: Implications for vascular inflammation and thrombosis

Peerschke, E. I. B., Yin, W., & Ghebrehiwet, B. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.05.009 · Cited by 251

Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells

Monsinjon, T., Gasque, P., Chan, P., Ischenko, A. M., Brady, J. J., & Fontaine, M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0737com · Cited by 249

Complement activation in patients with COVID-19: A novel therapeutic target

Cugno, M., Meroni, P. L., Gualtierotti, R., Griffini, S., Grovetti, E., Torri, A., Panigada, M., Aliberti, S., Blasi, F., Tedesco, F., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.006 · Cited by 247

Protective Role of the Angiotensin AT 2 Receptor in a Renal Wrap Hypertension Model

Siragy, H. M., & Carey, R. M. (1999) · Hypertension · doi:10.1161/01.hyp.33.5.1237 · Cited by 246

Complement C3a and C5a Induce Different Signal Transduction Cascades in Endothelial Cells

Schraufstätter, I. U., Trieu, K., Sikora, L., Sriramarao, P., & DiScipio, R. G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.4.2102 · Cited by 233

Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II–Renin Feedback Interruption

Azizi, M., Ménard, J., Bissery, A., Guyenne, T.-T., Bura-Rivière, A., Vaidyanathan, S., & Camisasca, R. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000146686.35541.29 · Cited by 233

Inactivation of C3a and C5a Octapeptides by Carboxypeptidase R and Carboxypeptidase N

Campbell, W. D., Lazoura, E., Okada, N., & Okada, H. (2002) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2002.tb02669.x · Cited by 224

SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation

Yan, B., Freiwald, T., Chauss, D., Wang, L., West, E. E., Mirabelli, C., Zhang, C. J., Nichols, E.-M., Malik, N. T., Gregory, R., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg0833 · Cited by 222

Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R).

Joseph, K., Ghebrehiwet, B., Peerschke, E. I. B., Reid, K. B. M., & Kaplan, A. P. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8552 · Cited by 217

Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.

Rinder, C. S., Rinder, H. M., Smith, B. R., Fitch, J. C. K., Smith, M. J., Tracey, J. B., Matis, L. A., Squinto, S. P., & Rollins, S. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118195 · Cited by 213

Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin

Fields, T. R., Ghebrehiwet, B., & Kaplan, A. P. (1983) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(83)90052-0 · Cited by 208

Human platelet activation by C3a and C3a des-arg.

Polley, M. J., & Nachman, R. L. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.158.2.603 · Cited by 207

The membrane attack complex as an inflammatory trigger

Morgan, B. P. (2016) · Immunobiology · doi:10.1016/j.imbio.2015.04.006 · Cited by 205

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Vlaar, A. P. J., de Bruin, S., Busch, M. H., Timmermans, S. A. M. E. G., van Zeggeren, I. E., Koning, R., ter Horst, L., Bulle, E., van Baarle, F. L. F., van der Horst, I. C. C., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30341-6 · Cited by 203

Mechanisms of activation of the classical pathway of complement by Hageman factor fragment.

Ghebrehiwet, B., Randazzo, B. P., Dunn, J. T., et al. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110898 · Cited by 197

Mass-Spectrometric Identification of a Novel Angiotensin Peptide in Human Plasma

Jankowski, V., Vanholder, R. C., van der Giet, M., Tölle, M., Karadogan, S., Gobom, J., Furkert, J., Oksche, A., Krause, E., Tran, T. N. A., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000253889.09765.5f · Cited by 197

Complement in ANCA-associated vasculitis: mechanisms and implications for management

Chen, M., Jayne, D. R. W., & Zhao, M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.37 · Cited by 197

Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein.

Wiggins, R. C., Bouma, B. N., Cochrane, C. G., & Griffin, J. H. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4636 · Cited by 188

The plasma bradykinin-forming pathways and its interrelationships with complement

Kaplan, A. P., & Ghebrehiwet, B. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.05.010 · Cited by 181

Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs

Jalowy, A., Schulz, R., Dörge, H., Behrends, M., & Heusch, G. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00441-0 · Cited by 179

Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study

Annane, D., Heming, N., Grimaldi‐Bensouda, L., Frémeaux‐Bacchi, V., Vigan, M., Roux, A.-L., Marchal, A., Michelon, H., Rottman, M., & Moine, P. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100590 · Cited by 174

Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia

Taus, F., Salvagno, G. L., Canè, S., Fava, C., Mazzaferri, F., Carrara, E., Petrova, V., Barouni, R. M., Dima, F., Dalbeni, A., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315175 · Cited by 171

The role of C5a in acute lung injury induced by highly pathogenic viral infections

Wang, R., He, X., Guo, R., Li, Y., & Shen, B. (2015) · Emerging Microbes & Infections · doi:10.1038/emi.2015.28 · Cited by 168

HAE Pathophysiology and Underlying Mechanisms

Zuraw, B. L., & Christiansen, S. C. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8561-8 · Cited by 164

Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma.

Revak, S. D., Cochrane, C. G., Bouma, B. N., et al. (1978) · The Journal of Experimental Medicine · doi:10.1084/jem.147.3.719 · Cited by 162

Angiotensin II Type 2 Receptor–Bradykinin B 2 Receptor Functional Heterodimerization

Abadir, P. M., Periasamy, A., Carey, R. M., & Siragy, H. M. (2006) · Hypertension · doi:10.1161/01.hyp.0000228997.88162.a8 · Cited by 162

Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney.

Odya, C. E., Marinkovic, D. V., Hammon, K. J., et al. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34557-x · Cited by 159

Human carboxypeptidase M

Skidgel, R. A., Davis, R. M., & Tan, F. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)94167-0 · Cited by 158

Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab

Rambaldi, A., Gritti, G., Micò, M. C., Frigeni, M., Borleri, G., Salvi, A., Landi, F., Pavoni, C., Sonzogni, A., Gianatti, A., et al. (2020) · Immunobiology · doi:10.1016/j.imbio.2020.152001 · Cited by 157

Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors

Kuhr, F., Lowry, J., Zhang, Y., Brovkovych, V. M., & Skidgel, R. A. (2010) · Neuropeptides · doi:10.1016/j.npep.2009.12.004 · Cited by 154

Angiotensin AT 2 Receptors Directly Stimulate Renal Nitric Oxide in Bradykinin B 2 -Receptor–Null Mice

Abadir, P. M., Carey, R. M., & Siragy, H. M. (2003) · Hypertension · doi:10.1161/01.hyp.0000090323.58122.5c · Cited by 154

Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross‐talk act as a linchpin in the events leading to thromboinflammation

Ekdahl, K., Teramura, Y., Hamad, O., Asif, S., Duehrkop, C., Fromell, K., Gustafson, E., Hong, J., Kozarcanin, H., Magnusson, P., et al. (2016) · Immunological Reviews · doi:10.1111/imr.12471 · Cited by 154

The Binding Protein for Globular Heads of Complement C1q, gC1qR

Lim, B. L., Reid, K. B. M., Ghebrehiwet, B., Peerschke, E. I. B., LEIGH, L. E. A., & Preissner, K. T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.43.26739 · Cited by 153

The polyphosphate–factor XII pathway drives coagulation in prostate cancer-associated thrombosis

Nickel, K. F., Ronquist, G. K., Länger, F. P., et al. (2015) · Blood · doi:10.1182/blood-2015-01-622811 · Cited by 152

Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis

Merkulov, S. M., Zhang, W.-M., Komar, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-06-092338 · Cited by 150

Novel RAAS agonists and antagonists: clinical applications and controversies

Romero, C. A., Orías, M., & Weir, M. R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.6 · Cited by 148

Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII

Joseph, K., Tholanikunnel, B. G., & Kaplan, A. P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022626899 · Cited by 148

The Complement Receptor C5aR2: A Powerful Modulator of Innate and Adaptive Immunity

Li, X. X., Lee, J. D., Kemper, C., & Woodruff, T. M. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900371 · Cited by 148

Proteomic and Metabolomic Characterization of COVID-19 Patient SeraPreprint

Shen, B., Yi, X., Sun, Y., et al. (2020) · medRxiv · doi:10.1101/2020.04.07.20054585 · Cited by 148

Blockade of Bradykinin Receptor B1 but Not Bradykinin Receptor B2 Provides Protection From Cerebral Infarction and Brain Edema

Austinat, M., Braeuninger, S., Pesquero, J. B., Brede, M., Bäder, M., Stoll, G., Renné, T., & Kleinschnitz, C. (2008) · Stroke · doi:10.1161/strokeaha.108.526673 · Cited by 145

An Oral Formulation of Angiotensin-(1-7) Produces Cardioprotective Effects in Infarcted and Isoproterenol-Treated Rats

Marques, F. D., Ferreira, A. J., Sinisterra, R. D., et al. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.167346 · Cited by 145

Factor XII and uPAR upregulate neutrophil functions to influence wound healing

Stavrou, E. X., Fang, C., Bane, K. L., Long, A. T., Naudin, C., Kucukal, E., Gandhi, A., Brett-Morris, A., Mumaw, M. M., Izadmehr, S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci92880 · Cited by 145

Kallikrein Cleaves C3 and Activates Complement

Irmscher, S., Döring, N., Halder, L. D., Jo, E. A. H., Kopka, I., Dunker, C., Jacobsen, I. D., Luo, S., Slevogt, H., Stefan Lorkowski, A., et al. (2017) · Journal of Innate Immunity · doi:10.1159/000484257 · Cited by 143

Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations

Diorio, C. J., McNerney, K. O., Lambert, M. P., Paessler, M. E., Anderson, E. M., Henrickson, S. E., Chase, J. M., Liebling, E. J., Burudpakdee, C., Lee, J. H., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003471 · Cited by 141

Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation

Ståhl, A.-L., Vaziri‐Sani, F., Heinen, S., Kristoffersson, A., GYDELL, K., Raafat, R. H., Gutiérrez, A., Beringer, O., Zipfel, P. F., & Karpman, D. (2008) · Blood · doi:10.1182/blood-2007-08-106153 · Cited by 139

Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients

Wu, Z., Hu, R., Zhang, C., Ren, W., Yu, A., & Zhou, X. (2020) · Critical Care · doi:10.1186/s13054-020-03015-0 · Cited by 138

SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy

Chung, M. K., Karnik, S. S., Saef, J., Bergmann, C. C., Barnard, J., Lederman, M. M., Tilton, J. C., Cheng, F., Harding, C. V., Young, J. B., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102907 · Cited by 138

Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis

Kourtzelis, I., Markiewski, M. M., Doumas, M. N., Rafail, S., Kambas, K., Mitroulis, I., Panagoutsos, S. A., Passadakis, P., Vargemezis, V., Magotti, P., et al. (2010) · Blood · doi:10.1182/blood-2010-01-264051 · Cited by 137

The (pro)renin receptor in health and disease

Ichihara, A., & Yatabe, M. S. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0160-5 · Cited by 137

Microvascular effects of anaphylatoxins C3a and C5a.

Björk, J., Hugli, T. E., & Smedegård, G. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.134.2.1115 · Cited by 134

G-Protein–Coupled Receptor MrgD Is a Receptor for Angiotensin-(1–7) Involving Adenylyl Cyclase, cAMP, and Phosphokinase A

Tetzner, A., Gebolys, K., Meinert, C., Klein, S., Uhlich, A., Trebicka, J., Villacañas, Ó., & Walther, T. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07572 · Cited by 134

Promotion of Hypercoagulability in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis by C5a‐Induced Tissue Factor–Expressing Microparticles and Neutrophil Extracellular Traps

Huang, Y., Wang, H., Wang, C., Chen, M., & Zhao, M. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39239 · Cited by 132

Shiga Toxin and Lipopolysaccharide Induce Platelet-Leukocyte Aggregates and Tissue Factor Release, a Thrombotic Mechanism in Hemolytic Uremic Syndrome

Ståhl, A.-L., Sartz, L., Nelsson, A., Békássy, Z. D., & Karpman, D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006990 · Cited by 132

Kallikreins – The melting pot of activity and function

Kalińska, M., Meyer‐Hoffert, U., Kantyka, T., & Potempa, J. (2015) · Biochimie · doi:10.1016/j.biochi.2015.09.023 · Cited by 131

Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain.

Thompson, R. E., Mandle, R. J., & Kaplan, A. P. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.10.4862 · Cited by 128

Complement Activation in Angiotensin II–Induced Organ Damage

Shagdarsuren, E., Wellner, M., Bräsen, J. H., Park, J.-K., Fiebeler, A., Henke, N., Dechend, R., Gratze, P., Luft, F. C., & Müller, D. N. (2005) · Circulation Research · doi:10.1161/01.res.0000182677.89816.38 · Cited by 128

Bradykinin receptors: Agonists, antagonists, expression, signaling, and adaptation to sustained stimulation

Marceau, F., Bachelard, H., Bouthillier, J., Fortin, J., Morissette, G., Bawolak, M., Charest‐Morin, X., & Gera, L. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106305 · Cited by 127

Diminished Cardioprotective Response to Inhibition of Angiotensin-Converting Enzyme and Angiotensin II Type 1 Receptor in B2Kinin Receptor Gene Knockout Mice

Yang, X.-P., Liu, Y.-H., Mehta, D., et al. (2001) · Circulation Research · doi:10.1161/hh1001.090759 · Cited by 126

Control of Renin Synthesis and Secretion

Kurtz, A. (2012) · American Journal of Hypertension · doi:10.1038/ajh.2011.246 · Cited by 125

Chymase-Dependent Generation of Angiotensin II from Angiotensin-(1-12) in Human Atrial Tissue

Ahmad, S., Simmons, T. W., Varagić, J., Moniwa, N., Chappell, M. C., & Ferrario, C. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028501 · Cited by 124

Cleavage of Kininogen and Subsequent Bradykinin Release by the Complement Component: Mannose-Binding Lectin-Associated Serine Protease (MASP)-1

Dobó, J., Major, B., Kékesi, K. A., Szabó, I., Megyeri, M., Hajela, K., Juhász, G. D., Závodszky, P., & Gál, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020036 · Cited by 124

Angiotensin II Induces Neutrophil Accumulation In Vivo Through Generation and Release of CXC Chemokines

Nabah, Y. N. A., Mateo, T., Estellés, R., Mata, M., Zagorski, J., Sarau, H., Cortijo, J., Morcillo, E. J., Jose, P. J., & Sanz, M.-J. (2004) · Circulation · doi:10.1161/01.cir.0000148824.93600.f3 · Cited by 124

Complement component C3a plays a critical role in endothelial activation and leukocyte recruitment into the brain

Wu, F., Zou, Q., Ding, X., Shi, D., Zhu, X., Hu, W., Liu, L., & Zhou, H. Y. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0485-y · Cited by 124

Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis

Sauter, M., Sauter, M., Reis, E. S., Emschermann, F., Nording, H., Ebenhöch, S., Kraft, P., Münzer, P., Mauler, M., Rheinlaender, J., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034600 · Cited by 123

Effects of MASP-1 of the Complement System on Activation of Coagulation Factors and Plasma Clot Formation

Heß, K., Ajjan, R., Phoenix, F. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035690 · Cited by 120

Vascular Response to Angiotensin II Is Exaggerated through an Upregulation of AT1 Receptor in AT2 Knockout Mice

Tanaka, M., Tsuchida, S., Imai, T., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0500 · Cited by 118

AT2 receptors in cardiovascular and renal diseases

Kaschina, E., Namsolleck, P., & Unger, T. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.008 · Cited by 117

The activation of the alternative pathway C3 convertase by human plasma kallikrein.

DiScipio, R. G. (1982) · PubMed · Cited by 115

Synergistic effect of angiotensin-(1–7) on bradykinin arteriolar dilation in vivo

Oliveira, M. A., Fortes, Z. B., Santos, R. A. S., et al. (1999) · Peptides · doi:10.1016/s0196-9781(99)00123-0 · Cited by 115

The plasma kallikrein-kinin system counterbalances the renin-angiotensin system

Schmaier, A. H. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15490 · Cited by 115

High Molecular Weight Kininogen Utilizes Heparan Sulfate Proteoglycans for Accumulation on Endothelial Cells

Renné, T., Dedio, J., David, G., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000313200 · Cited by 115

AT2Receptor Activation Induces Natriuresis and Lowers Blood Pressure

Kemp, B. A., Howell, N. L., Gildea, J. J., et al. (2014) · Circulation Research · doi:10.1161/circresaha.115.304110 · Cited by 115

Induction of Functional Bradykinin B 1 -Receptors in Normotensive Rats and Mice Under Chronic Angiotensin-Converting Enzyme Inhibitor Treatment

Marin‐Castaño, M. E., Schanstra, J. P., Neau, E., Praddaude, F., Pécher, C., Ader, J., Girolami, J., & Bascands, J. (2002) · Circulation · doi:10.1161/hc0502.102965 · Cited by 114

Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes

de Nooijer, A., Grondman, I., Janssen, N. A. F., Netea, M. G., Willems, L., van de Veerdonk, F. L., Giamarellos‐Bourboulis, E. J., Toonen, E. J. M., Joosten, L. A. B., RCI-COVID-19 study group, et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa646 · Cited by 114

Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema

Aygören‐Pürsün, E., Bygum, A., Grivcheva‐Panovska, V., Magerl, M. A. K., Graff, J., Steiner, U. C., Fain, O., Huissoon, A. P., Kinaciyan, T., Farkas, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716995 · Cited by 113

Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence

Bork, K., Machnig, T., Wulff, K., et al. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01570-x · Cited by 113

Cardioprotective Angiotensin-(1–7) Peptide Acts as a Natural-Biased Ligand at the Angiotensin II Type 1 Receptor

Galandrin, S., Denis, C., Boularan, C., Marie, J., M’Kadmi, C., Pilette, C., Dubroca, C., Nicaise, Y., Séguélas, M., N’Guyen, D., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.08118 · Cited by 112

Antihypertensive Drugs and COVID-19 Risk

Semenzato, L., Botton, J., Drouin, J., Baricault, B., Vabre, C., Cuenot, F., Penso, L., Herlemont, P., Sbidian, É., Weill, A., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16314 · Cited by 112

Enzymatic pathways in the pathogenesis of hereditary angioedema: The role of C1 inhibitor therapy

Kaplan, A. P. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.08.012 · Cited by 111

Role of Bradykinin in the Cardiac Effects of Angiotensin-Converting Enzyme Inhibitors

Linz, W., & Schölkens, B. A. (1992) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199200209-00015 · Cited by 110

Angiotensin 1–9 and 1–7 release in human heart role of cathepsin, A

Jackman, H. L., Massad, M. G., Sekosan, M., Tan, F., Brovkovych, V., Marcic, B. M., & Erdös, E. G. (2002) · Hypertension · doi:10.1161/01.hyp.0000017283.67962.02 · Cited by 110

ACE2 Elevation in Severe COVID-19

Reindl‐Schwaighofer, R., Hödlmoser, S., Eskandary, F. A., Poglitsch, M., Bonderman, D., Straßl, R. P., Aberle, J. H., Oberbauer, R. W., Zoufaly, A., & Hecking, M. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202101-0142le · Cited by 109

Enhancement of Bradykinin and Resensitization of Its B2Receptor

Marcic, B. M., Deddish, P. A., Jackman, H. L., & Erdös, E. G. (1999) · Hypertension · doi:10.1161/01.hyp.33.3.835 · Cited by 108

Evidence for Heterodimerization and Functional Interaction of the Angiotensin Type 2 Receptor and the Receptor MAS

Leonhardt, J., Villela, D. C., Teichmann, A., Munter, L. M., Mayer, M., Mardahl, M., Kirsch, S., Namsolleck, P., Lucht, K., Benz, V., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08814 · Cited by 108

Bradykinin and Its Metabolite, Arg-Pro-Pro-Gly-Phe, Are Selective Inhibitors of α-Thrombin–Induced Platelet Activation

Hasan, A., Amenta, S., & Schmaier, A. H. (1996) · Circulation · doi:10.1161/01.cir.94.3.517 · Cited by 107

Roles of Factor XII in Innate Immunity

Renné, T., & Stavrou, E. X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02011 · Cited by 107

Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19

Rieder, M., Wirth, L., Pollmeier, L., et al. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa169 · Cited by 107

Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation

Göb, E., Reymann, S., Langhauser, F., Schuhmann, M. K., Kraft, P., Thielmann, I., Göbel, K., Brede, M., Homola, G. A., Solymosi, L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24380 · Cited by 105

Platelet-Activating Factor and Kinin-Dependent Vascular Leakage as a Novel Functional Activity of the Soluble Terminal Complement Complex

Bossi, F., Fabio Fischetti, I., Pellis, V., Bulla, R., Ferrero, E., Mollnes, T. E., Regoli, D. C., & Tedesco, F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6921 · Cited by 104

Bradykinin Potentiation by Angiotensin-(1-7) and ACE Inhibitors Correlates With ACE C- and N-Domain Blockade

Tom, B., VRIES, R. D., Saxena, P. R., et al. (2001) · Hypertension · doi:10.1161/01.hyp.38.1.95 · Cited by 104

Angiotensin 1–7 Induces Bradykinin-Mediated Relaxation in Porcine Coronary Artery

Gorelik, G. J., Carbini, L. A., & Scicli, A. G. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37600-1 · Cited by 102

Angiotensin II–Mediated Microvascular Thrombosis

Senchenkova, E. Y., Russell, J., Almeida-Paula, L. D., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.158220 · Cited by 101

Inhibition of Bradykinin Receptor B1 Protects Mice from Focal Brain Injury by Reducing Blood–Brain Barrier Leakage and Inflammation

Raslan, F., Schwarz, T. J., Meuth, S., Austinat, M., Bader, M., Renné, T., Roosen, K., Stoll, G., Sirén, A., & Kleinschnitz, C. (2010) · Journal of Cerebral Blood Flow and Metabolism · doi:10.1038/jcbfm.2010.28 · Cited by 100

Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4

Wang, H., Ricklin, D., & Lambris, J. D. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707364114 · Cited by 100

ACE inhibitor-mediated angioedema

Montinaro, V., & Cicardi, M. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106081 · Cited by 100

Key developments in renin–angiotensin–aldosterone system inhibition

Pessôa, B. S., van der Lubbe, N., Verdonk, K., Roks, A. J. M., Hoorn, E. J., & Danser, A. H. J. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.249 · Cited by 99

A Novel Inflammatory Pathway Involved in Leukocyte Recruitment: Role for the Kinin B1 Receptor and the Chemokine CXCL5

Duchêne, J., Lecomte, F. M. J., Ahmed, S. U. M., Cayla, C., Pesquero, J. B., Bäder, M., Perretti, M., & Ahluwalia, A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4849 · Cited by 99

The plasma kallikrein-kinin system counterbalances the renin-angiotensin system

Schmaier, A. H. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215490 · Cited by 97

Angiotensin III: A physiological relevant peptide of the renin angiotensin system

Yugandhar, V. G., & Clark, M. A. (2013) · Peptides · doi:10.1016/j.peptides.2013.04.014 · Cited by 96

Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes.

Harpel, P. C., Lewin, M., & Kaplan, A. P. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89258-4 · Cited by 93

AT2 receptor‐dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions

Katada, J., & Majima, M. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704731 · Cited by 93

Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs

Wilbs, J., Kong, X., Middendorp, S. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17648-w · Cited by 93

Deficiency of complement C3a and C5a receptors prevents angiotensin II–induced hypertension via regulatory T cells

Chen, X.-H., Ruan, C.-C., Ge, Q., Ma, Y., Xu, J.-Z., Zhang, Z.-B., Lin, J.-R., Chen, D.-R., Zhu, D.-L., & Gao, P.-J. (2018) · Circulation Research · doi:10.1161/circresaha.117.312153 · Cited by 92

Complement Activation in Kidneys of Patients With COVID-19

Pfister, F., Vonbrunn, E., Ries, T., Jäck, H., Überla, K., Lochnit, G., Sheriff, A., i, M. H., Büttner-Herold, M. J., Amann, K., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594849 · Cited by 91

Reduced thrombosis in Klkb1−/− mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor

Stavrou, E. X., Fang, C., Merkulova, A. A., Alhalabi, O., Grobe, N., Antoniak, S., Mackman, N., & Schmaier, A. H. (2014) · Blood · doi:10.1182/blood-2014-01-550285 · Cited by 90

Mannose-Binding Lectin-Associated Serine Protease-1 Is a Significant Contributor to Coagulation in a Murine Model of Occlusive Thrombosis

Bonte, L. R. L., Pavlov, V. I., Tan, Y. S., Takahashi, K., Takahashi, M., Banda, N. K., Zou, C., Fujita, T., & Stahl, G. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102916 · Cited by 89

Human complement in thrombin-mediated platelet function: uptake of the C5b-9 complex.

Polley, M. J., & Nachman, R. L. (1979) · The Journal of Experimental Medicine · doi:10.1084/jem.150.3.633 · Cited by 87

Hereditary angioedema: the plasma contact system out of control

de Maat, S., Hofman, Z. L. M., & Maas, C. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14209 · Cited by 86

Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2−/− mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation

Fang, C., Stavrou, E. X., Schmaier, A. A., Grobe, N., Morris, M., Chen, A., Nieman, M. T., Adams, G. N., Larusch, G. A., Zhou, Y., et al. (2013) · Blood · doi:10.1182/blood-2012-09-459156 · Cited by 84

Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System

Urwyler, P., Moser, S., Charitos, P., Heijnen, I., Rudin, M., Sommer, G., Giannetti, B., Bassetti, S., Sendi, P., Trendelenburg, M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02072 · Cited by 84

Kallidin- and Bradykinin-Degrading Pathways in Human Heart

Kokkonen, J. O., Kuoppala, A., Saarinen, J., Lindstedt, K. A., & Kovanen, P. T. (1999) · Circulation · doi:10.1161/01.cir.99.15.1984 · Cited by 82

Activation of kinin B1 receptors induces chemotaxis of human neutrophils

Ehrenfeld, P., Millán, C., Matus, C. E., Figueroa, J. E., Burgos, R. A., Nualart, F., Bhoola, K. D., & Figueroa, C. D. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1205744 · Cited by 82

Kinin B1 receptors as a therapeutic target for inflammation

Qadri, F., & Bäder, M. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1409724 · Cited by 82

Circulating versus tissue renin-angiotensin system: On the origin of (pro)renin

Krop, M., & Danser, A. H. J. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0022-1 · Cited by 81

Angiotensin and vascular fibrinolytic balance

Vaughan, D. A. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(01)02273-7 · Cited by 80

Cross-talk between the complement and the kinin system in vascular permeability

Bossi, F., Peerschke, E. I. B., Ghebrehiwet, B., & Tedesco, F. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.06.006 · Cited by 80

The Regulation of the Inflammatory Response Through Nuclear Factor-κB Pathway by Angiotensin IV Extends the Role of the Renin Angiotensin System in Cardiovascular Diseases

Ruiz‐Ortega, M., Esteban, V., & Egido, J. (2007) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2006.10.003 · Cited by 77

The C1q Receptors: Focus on gC1qR/p33 (C1qBP, p32, HABP-1)1.

Ghebrehiwet, B., Geisbrecht, B., Xu, X., Savitt, A. G., & Peerschke, E. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101338 · Cited by 76

Induction of cellular procoagulant activity by the membrane attack complex of complement

Sims, P. J., & Wiedmer, T. (1995) · Seminars in Cell Biology · doi:10.1006/scel.1995.0037 · Cited by 75

Aliskiren inhibits renin-mediated complement activation

Békássy, Z. D., Kristoffersson, A., Rebetz, J., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.04.004 · Cited by 75

Complement 5a Receptor Mediates Angiotensin II–Induced Cardiac Inflammation and Remodeling

Zhang, C., Li, Y., Wang, C., Wu, Y., Cui, W., Miwa, T., Sato, S., Li, H., Song, W., & Du, J. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.303120 · Cited by 74

Activation of the Complement, Coagulation, Fibrinolytic and Kallikrein–Kinin Systems During Attacks of Hereditary Angioedema

Nielsen, E. W., Johansen, H. T., Högåsen, K., et al. (1996) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.1996.d01-298.x · Cited by 74

Neprilysin Inhibitors and Bradykinin

Campbell, D. J. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00257 · Cited by 72

Defining blood-induced microglia functions in neurodegeneration through multiomic profiling

Mendiola, A. S., Yan, Z., Dixit, K., Johnson, J. R., Bouhaddou, M., Meyer-Franke, A., Shin, M.-G., Yong, Y., Agrawal, A., MacDonald, E., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01522-0 · Cited by 124

Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis

Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030389 · Cited by 98

Transplantation of human umbilical cord-derived mesenchymal stem cells improves age-related ovarian functional decline via regulating the local renin–angiotensin system on inflammation and oxidative stress

Wei, L., Bo, L., Luo, C., Yin, N., Jiang, W., Qian, F., Zhou, A., Lu, X., Guo, H., & Mao, C. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03997-6 · Cited by 11

Trypstatin as a Novel TMPRSS2 Inhibitor with Broad‐Spectrum Efficacy against Corona and Influenza Viruses

Lawrenz, J., Wettstein, L., Rodríguez Alfonso, A., Nchioua, R., von Maltitz, P., Albers, D. P. J., Zech, F., Vandeput, J., Naesens, L., Fois, G., et al. (2025) · Advanced Science · doi:10.1002/advs.202506430 · Cited by 8

Pharmacological properties of T-kinin (isoleucyl-seryl-bradykinin) from rat plasma

Okamoto, H., & Greenbaum, L. M. (1983) · Biochemical Pharmacology · doi:10.1016/0006-2952(83)90039-4 · Cited by 49

Pharmacological characterization of kinin‐induced relaxation of human corpus cavernosum

Teixeira, Moreno, Ferreira, Netto‐Jr, R., Fregonesi, Antunes, E., & Nucci, G. D. (1998) · British Journal of Urology · doi:10.1046/j.1464-410x.1998.00533.x · Cited by 27

Methionyl-lysyl-bradykinin, a new kinin from ox blood

Elliott, D. F., & Lewis, G. (1965) · Biochemical Journal · doi:10.1042/bj0950437 · Cited by 69

Bradykininogen in the Blood of Women during Pregnancy, Labor, and Puerperium

Periti, P., & Gasparri, F. (1966) · Springer eBooks · doi:10.1007/978-3-642-94965-4_50 · Cited by 6

The actions of kinin antagonists on B1 and B2 receptor systems

Regoli, D. C., Drapeau, G., Rovero, P., et al. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90687-4 · Cited by 91